徐晤,王志荣,李思召,张超群,李飞,周召峰,张卓琦

• 1:徐州医学院附属医院心内科

摘要(Abstract)：

目的建立猪实验性心房颤动(atrial fibrillation,AF)模型,观察心房结构重构的变化和替米沙坦(TMST)干预的作用,测定血管紧张素转化酶2(ACE2)和胶原蛋白-Ⅰ的变化。方法将18头猪按随机数字表分为对照组(NC组)、快速心房起搏组(RAP组)、RAP+TMST组。闭胸法建立猪的持续性AF模型,超声测量实验前、后心室收缩末期左、右心房面积(LAESA、RAESA)变化;应用程序刺激检测AF的诱发率和持续时间;通过伊红(HE)染色、Masson染色和蛋白印迹法(Western blot)检测ACE2和胶原蛋白-Ⅰ的变化。结果与RAP组相比,RAP+TMST组LAESA、RAESA扩大减轻,AF诱发率降低、持续时间缩短,胶原蛋白-Ⅰ减少,而ACE2表达明显增加。RAESA与胶原蛋白-Ⅰ呈正相关关系(r1=0.956,P<0.01),RAESE与ACE2、ACE2与胶原蛋白-Ⅰ均呈负相关关系(r2=-0.966,r3=-0.948,P<0.01)。结论猪AF模型心房肌出现结构重构的病理表现,ACE2表达失衡与AF结构重构密切相关;TMST可降低AF的发生率及持续时间,明显改善心房结构重构。

关键词(KeyWords)： 心房颤动;起搏,人工;心房重构;肽基二肽酶A;替米沙坦

Abstract:

Keywords:

基金项目(Foundation): 江苏省兴卫工程医学重点人才资助项目(RC2007089)

作者(Author): 徐晤,王志荣,李思召,张超群,李飞,周召峰,张卓琦

参考文献(References)：

• [1]Naccarelli GV,Johnston SS,Lin J,et al.Cost burden of cardiovascular hospitalization and mortality in A THENA-like patients with atrial fibrillation/atrial flutter in the United States.Clin Cardiol,2010,33:270-279.
• [2]Healey JS,Morillo CA,Connolly SJ.Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.Curr Opin Cardiol,2005,20:31-37.
• [3]Chen CL,Lin JL,Lai LP,et al.Altered expression of FHL1,CARP,TSC-22and P311provide insights into complex transcriptional regulation in pacing-induced atrial fibrillation.Biochim Biophys Acta,2007,1772:317-329.
• [4]Laurent G,Moe G,Hu X,et al.Experimental studies of atrial fibrillation:a comparison of two pacing models.Am J Physiol Heart Circ Physiol,2008,294:H1206-H1215.
• [5]耿宁,孙英贤,Sunny PO,等.通过刺激自主神经结丛建立持续局灶性心房颤动动物模型.中国介入心脏病学杂志,2006,14:162-166.
• [6]Schotten U,Verheule S,Kirchhof P,et al.Pathophysiological mechanisms of atrial fibrillation:a translational appraisal.Physiol Rev,2011,91:265-325.
• [7]Li Y,Li W,Yang B,et al.Effects of Cilazapril on atrial electrical,structural and functional remodeling in atrial fibrillation dogs.J Electrocardiol,2007,40:100e1-e6.
• [8]Ishiyama Y,Gallagher PE,Averill DB,et al.Upregulation of angiotensin-converting enzyme2after myocardial infarction by blockade of angiotensinⅡreceptors.Hypertension,2004,43:970-976.
• [9]Keidar S,Kaplan M,Gamliel-Lazarovich A.ACE2of the heart:From angiotensin I to angiotensin(1-7).Cardiovasc Res,2007,73:463-469.
• [10]Frampton JE.Telmisartan:a review of its use in cardiovascular disease prevention.Drugs,2011,71:651-677.